Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

News

Health Care

Trading Ideas

General

AGIO

CRBP

CRBU

RBC&#39;s Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.

Attention Biotech Investors - Stocks To Watch From RBC Global Healthcare Conference

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

DNUT

FAAS

FRGE

IVVD

KRUS

VTYX

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday&#39;s Pre-Market Session

Earnings

DLTR

NVDA

PACK

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the &#34;Greed&#34; zone on Tuesday.

Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points

Caribou Biosciences Inc

Press Releases

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU

Legal

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc. (CRBU) Shareholders

Caribou Biosciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; February 24, 2025 Deadline to file Lead Plaintiff Motion

CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

Anixa Biosciences

Atossa Therapeutics

Biomea Fusion

Cabaletta Bio

C4 Therapeutics

Coherus Oncology

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Elicio Therapeutics

EXoZymes

Genelux

HilleVax

IO Biotech

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Invivyd

Korro Bio

Lexeo Therapeutics

Macrogenics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Senti Biosciences

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TScan Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

B of A Securities

Citigroup

RBC Capital

Truist Securities

Comments

Caribou Biosciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell